Melanoma vaccines
/in International Publications, Malignant Melanoma /von 2008-09-01 / Expert Rev Vaccines 2008 Sep;7(7):937-49Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters
/in International Publications, Malignant Melanoma /von 2008-08-22 / Cancer Immunol. Immunother. 2009 Jan;58(1):1-14Dendritic cell vaccines in metastasized malignant melanoma
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2008-08-01 / G Ital Dermatol Venereol 2008 Aug;143(4):235-50TIMP-1-GPI in combination with hyperthermic treatment of melanoma increases sensitivity to FAS-mediated apoptosis
/in Hyperthermia, International Publications, Malignant Melanoma /von 2008-07-11 / Cancer Immunol. Immunother. 2009 Mar;58(3):361-71Strategies to overcome obstacles to successful immunotherapy of melanoma
/in International Publications, Malignant Melanoma /von 2008-07-01 / Int J Immunopathol Pharmacol 2008 Jul-Sep;21(3):493-500Phase I/II study of treatment with matured dendritic cells with or without low dose IL-2 in patients with disseminated melanoma
/in International Publications, Malignant Melanoma /von 2008-07-01 / Cancer Immunol. Immunother. 2008 Jul;57(7):1039-51Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor
/in International Publications, Malignant Melanoma /von 2008-07-01 / J. Clin. Oncol. 2008 Jul;26(19):3235-41IFN-producing killer dendritic cells contribute to the inhibitory effect of poly I:C on the progression of murine melanoma
/in International Publications, Malignant Melanoma /von 2008-07-01 / J. Immunother. 2008 Jul-Aug;31(6):555-62Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma
/in International Publications, Malignant Melanoma /von 2008-07-01 / J. Immunother. 2008 Jul-Aug;31(6):591-8
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution